First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - ScienceDirect

Figure 1 from Molecular Pathways: Fatty Acid Synthase

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640

FASN inhibitor TVB-3166 prevents S-acylation of the spike protein

First-in-human study of the safety, pharmacokinetics, and

Frontiers Translational Pharmacokinetic–Pharmacodynamic Modeling

PDF) Metabolic dysregulation and emerging therapeutical targets

Suppressing fatty acid synthase by type I interferon and chemical

Frontiers First-In-Human Study to Assess the Safety

Randomized, double-blinded, placebo-controlled phase I study of

PDF) Metabolic dysregulation and emerging therapeutical targets

Frontiers Pathogenetic, Prognostic, and Therapeutic Role of

Targeting fatty acid uptake and metabolism in cancer cells: A

Targeting fatty acid uptake and metabolism in cancer cells: A

Acetyl-CoA metabolism as a therapeutic target for cancer

First-in-human study of the safety, pharmacokinetics, and